한글목차

페그필그라스팀 바이오시밀러 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2025년 19억 2,000만 달러에서 2026년에는 20억 4,000만 달러에 이르고, CAGR 6.3%로 성장할 전망입니다. 지난 수년간의 성장에는 오리지널 의약품인 페그필그라스팀의 높은 비용, 바이오시밀러 공급 제한, 암 환자 수 증가, 화학요법 치료 증가, 호중구감소증 관리에 대한 인식 개선 등이 주요 요인으로 작용한 것으로 보입니다.

페그필그라스팀 바이오시밀러 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 26억 5,000만 달러에 이르고, CAGR은 6.7%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 신규 바이오시밀러 출시, 지지요법에서의 채택 확대, 병원 및 소매 약국 네트워크 확대, 바이오시밀러 사용에 대한 정부 장려책, 줄기세포 이식 요법에 대한 투자 증가 등을 들 수 있습니다. 예측 기간 동안 주요 동향으로는 암 지지요법에서 페그필그라스팀 바이오시밀러의 채택 확대, 병원 및 소매 약국 유통 채널 확대, 화학요법 유발 호중구감소증 완화에 대한 관심 증가, 조혈모세포 이식 및 말초혈액줄기세포 이식의 적용 확대, 만성 및 중증 선천성 호중구감소증 호중구감소증 치료에 대한 투자 증가 등을 들 수 있습니다.

암 발병률 증가는 페그필그라스팀 바이오시밀러 시장을 견인할 것으로 예측됩니다. 암은 통제할 수 없는 비정상적인 세포의 증식과 확산을 특징으로 하는 질병군을 말합니다. 암 유병률 증가는 주로 고령화에 기인하며, 고령화는 대부분의 암에서 가장 큰 위험요인이 되고, 대부분의 암은 65세 이상에서 발생합니다. 페그필그라스팀 바이오시밀러는 백혈구 생성을 촉진하여 화학요법 환자의 감염 위험을 감소시킵니다. 예를 들어, 영국 정부 산하 의료기관인 국민보건서비스(NHS)가 지난 10월 발표한 자료에 따르면, 2023년 신규 암 진단 건수는 35만 4,820건(하루 972건)으로 2022년 대비 8,605건 증가했다고 합니다. 이처럼 암 발생률 증가가 페그필그라스팀 바이오시밀러 시장을 견인하고 있는 것입니다.

페그필그라스팀 바이오시밀러 시장의 주요 기업들은 암 치료에서 안전하고 효과적이며 접근하기 쉬운 오리지널 생물학적 제제의 대체품을 제공하기 위해 고품질 바이오시밀러와 같은 바이오의약품 혁신을 추진하고 있습니다. 고품질 바이오시밀러는 레퍼런스 제품과 구조, 기능, 안전성, 유효성을 엄격하게 재현합니다. 예를 들어, 2023년 2월 독일 제약 및 의료 기술 전문 헬스케어 기업 프레제니우스 카비(Fresenius Kavi)는 미국 최초의 페그필그라스팀 바이오시밀러 '스팀펜드(Stimfened)'를 출시했습니다. 스팀펜드는 바늘 보호대가 부착된 일회용 프리필드시린지 6mg/0.6mL 용액으로 화학요법으로 인한 호중구감소증을 예방 및 치료하는 치료제입니다. 첨단 바이오시밀러 기술과 간편한 투약 방법을 결합한 스팀펜드는 고품질의 생물학적 제제 요법에 대한 접근성을 높입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Pegfilgrastim biosimilars are biosimilar drugs designed for use alongside supportive care in patients with non-myeloid cancers. They help prevent or treat infections caused by myelosuppressive chemotherapy by stimulating the production of specific white blood cells.

The main applications of pegfilgrastim biosimilars include chemotherapy treatment, transplantation, and other related uses. Chemotherapy involves the administration of one or more anti-cancer drugs according to a defined treatment protocol. These biosimilars are distributed through hospital pharmacies, retail pharmacies, and mail-order pharmacies.

Tariffs have impacted the pegfilgrastim biosimilars market by raising costs of imported biologics, raw materials, and formulation technologies. Hospital and retail pharmacies in regions such as North America and Europe, which depend heavily on imports, are most affected. This has increased treatment costs and slowed market penetration. On the positive side, tariffs have stimulated domestic manufacturing, encouraged local R&D, and promoted the development of cost-effective biosimilar alternatives, leading to broader accessibility over time.

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pegfilgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.92 billion in 2025 to $2.04 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high cost of originator pegfilgrastim, limited availability of biosimilars, growing cancer patient population, increasing chemotherapy procedures, rising awareness of neutropenia management.

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to launch of new biosimilars, increasing adoption in supportive oncology care, expansion of hospital and retail pharmacy networks, government incentives for biosimilar usage, rising investments in stem cell transplantation therapies. Major trends in the forecast period include rising adoption of pegfilgrastim biosimilars in supportive cancer care, expansion of hospital and retail pharmacy distribution channels, increasing focus on reducing chemotherapy-induced neutropenia, growth in hematopoietic and peripheral blood stem cell transplantation applications, rising investments in treatment of chronic and severe congenital neutropenia.

The climbing cancer incidence is set to drive the pegfilgrastim biosimilars market forward. Cancer encompasses disorders marked by uncontrolled abnormal cell growth and spread. Rising cancer prevalence largely stems from aging populations, as advanced age poses the biggest risk for most cancers, with most cases hitting those over 65. Pegfilgrastim biosimilars cut infection risks in chemo patients by spurring white blood cell production. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023-972 daily, up 8,605 from 2022. Therefore, the increased cancer incidence is driving the pegfilgrastim biosimilars market.

Leading companies in the pegfilgrastim biosimilars market are advancing biopharma innovations like high-quality biosimilars to deliver safe, potent, accessible substitutes for original biologics in cancer care. High-quality biosimilars closely mirror reference products in structure, function, safety, and effectiveness. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its first US pegfilgrastim biosimilar. Stimufend wards off and treats chemotherapy-induced neutropenia via a 6 mg/0.6 mL solution in a single-use pre-filled syringe with needle guard. Merging sophisticated biosimilar tech and user-friendly delivery, Stimufend advances access to premium biologic therapies.

In August 2025, Intas Pharmaceuticals Ltd., an India-based biotechnology company, acquired the UDENYCA from Coherus BioSciences, Inc. for an undisclosed amount. With this acquisition, Intas Pharmaceuticals and Accord BioPharma aim to strengthen their position as a global leader in pegfilgrastim, expand their FDA-approved biosimilar portfolio, and enhance patient access to high-quality, flexible treatment options for reducing the risk of infection in cancer patients. Coherus BioSciences Inc. is a US-based, commercial-stage biopharmaceutical company, focused on both biosimilars and innovative immuno-oncology therapies, with a team of industry veterans leveraging deep expertise in biologics development and commercialization.

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pegfilgrastim Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses pegfilgrastim biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pegfilgrastim biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pegfilgrastim biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Application: Chemotherapy Treatment; Transplantation; Other Applications
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail-Order Pharmacies
• 3) By Route of Administration: Prefilled Syringes (PFS); On-body Injectors (OBI); Other Routes
• Subsegments:
• 1) By Chemotherapy Treatment: Supportive Care for Cancer Patients; Reduction of Chemotherapy-Induced Neutropenia
• 2) By Transplantation: Hematopoietic Stem Cell Transplantation; Peripheral Blood Stem Cell Transplantation
• 3) By Other Applications: Treatment of Chronic Neutropenia; Treatment of Severe Congenital Neutropenia
• Companies Mentioned: Amgen; Mylan N.V.; Sandoz (a Novartis division); Teva Pharmaceutical Industries Ltd.; Biocon; Pfizer; Celltrion Healthcare; Coherus BioSciences; Gedeon Richter; Fresenius Kabi; Hetero Labs; Intas Pharmaceuticals; LG Chem; Merck KGaA; Zydus Cadila; Aurobindo Pharma; Apotex Inc.; Dr. Reddy's Laboratories; Stada Arzneimittel AG; Shanghai Henlius Biotech; Alvotech; EirGenix; Kye Pharmaceuticals; CinnaGen; Boryung Pharmaceutical; Sinopharm
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Pegfilgrastim Biosimilars Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Pegfilgrastim Biosimilars Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Pegfilgrastim Biosimilars Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Pegfilgrastim Biosimilars Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Pegfilgrastim Biosimilars In Supportive Cancer Care
  • 4.2.2 Expansion Of Hospital And Retail Pharmacy Distribution Channels
  • 4.2.3 Increasing Focus On Reducing Chemotherapy-Induced Neutropenia
  • 4.2.4 Growth In Hematopoietic And Peripheral Blood Stem Cell Transplantation Applications
  • 4.2.5 Rising Investments In Treatment Of Chronic And Severe Congenital Neutropenia

5. Pegfilgrastim Biosimilars Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Retail Pharmacies
• 5.3 Mail-Order Pharmacies
• 5.4 Oncology Centers
• 5.5 Cancer Treatment Clinics

6. Pegfilgrastim Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Pegfilgrastim Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Pegfilgrastim Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Pegfilgrastim Biosimilars Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Pegfilgrastim Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Pegfilgrastim Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Pegfilgrastim Biosimilars Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Pegfilgrastim Biosimilars Market Segmentation

• 9.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapy Treatment, Transplantation, Other Applications
• 9.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
• 9.3. Global Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes
• 9.4. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia
• 9.5. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
• 9.6. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

10. Pegfilgrastim Biosimilars Market Regional And Country Analysis

• 10.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Pegfilgrastim Biosimilars Market

• 11.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Pegfilgrastim Biosimilars Market

• 12.1. China Pegfilgrastim Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Pegfilgrastim Biosimilars Market

• 13.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Pegfilgrastim Biosimilars Market

• 14.1. Japan Pegfilgrastim Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Pegfilgrastim Biosimilars Market

• 15.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Pegfilgrastim Biosimilars Market

• 16.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Pegfilgrastim Biosimilars Market

• 17.1. South Korea Pegfilgrastim Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Pegfilgrastim Biosimilars Market

• 18.1. Taiwan Pegfilgrastim Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Pegfilgrastim Biosimilars Market

• 19.1. South East Asia Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Pegfilgrastim Biosimilars Market

• 20.1. Western Europe Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Pegfilgrastim Biosimilars Market

• 21.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Pegfilgrastim Biosimilars Market

• 22.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Pegfilgrastim Biosimilars Market

• 23.1. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Pegfilgrastim Biosimilars Market

• 24.1. Italy Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Pegfilgrastim Biosimilars Market

• 25.1. Spain Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Pegfilgrastim Biosimilars Market

• 26.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Pegfilgrastim Biosimilars Market

• 27.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Pegfilgrastim Biosimilars Market

• 28.1. North America Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Pegfilgrastim Biosimilars Market

• 29.1. USA Pegfilgrastim Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Pegfilgrastim Biosimilars Market

• 30.1. Canada Pegfilgrastim Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Pegfilgrastim Biosimilars Market

• 31.1. South America Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Pegfilgrastim Biosimilars Market

• 32.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Pegfilgrastim Biosimilars Market

• 33.1. Middle East Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Pegfilgrastim Biosimilars Market

• 34.1. Africa Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Pegfilgrastim Biosimilars Market Regulatory and Investment Landscape

36. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

• 36.1. Pegfilgrastim Biosimilars Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Pegfilgrastim Biosimilars Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Pegfilgrastim Biosimilars Market Company Profiles
  • 36.3.1. Amgen Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sandoz (a Novartis division) Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Biocon Overview, Products and Services, Strategy and Financial Analysis

37. Pegfilgrastim Biosimilars Market Other Major And Innovative Companies

• Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech

38. Global Pegfilgrastim Biosimilars Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

40. Pegfilgrastim Biosimilars Market High Potential Countries, Segments and Strategies

• 40.1 Pegfilgrastim Biosimilars Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Pegfilgrastim Biosimilars Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Pegfilgrastim Biosimilars Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer